科伦博泰生物(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06990 科伦博泰生物

已收盘 08-14 16:08:36

520.500

-5.000

-0.95%

最高528.500	最低511.000	成交量40.31万
今开528.500	昨收525.500	日振幅3.33%
总市值1,244亿	流通市值921.29亿	总股本2.39亿
成交额2.09亿	换手率0.23%	流通股本1.77亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06990","market":"HK","secType":"STK","nameCN":"科伦博泰生物","latestPrice":520.5,"timestamp":1786694916006,"preClose":525.5,"halted":0,"volume":403100,"delay":0,"changeRate":-0.009514747859181731,"floatShares":177000000,"shares":239000000,"eps":-1.9284393439535434,"marketStatus":"已收盘","change":-5,"latestTime":"08-14 16:08:36","open":528.5,"high":528.5,"low":511,"amount":209236947,"amplitude":0.033302,"askPrice":521,"askSize":1000,"bidPrice":520.5,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.9284393439535434,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786930200000},"marketStatusCode":5,"adr":0,"listingDate":1689004800000,"exchange":"SEHK","adjPreClose":525.5,"openAndCloseTimeList":[[1786671000000,1786680000000],[1786683600000,1786694400000]],"volumeRatio":0.704492,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06990","defaultTab":"news","newsList":[{"id":"1197703790","title":"异动解读｜科伦博泰生物盘中上涨3.15%，双载荷ADC获批临床叠加中报审议在即","url":"https://stock-news.laohu8.com/highlight/detail?id=1197703790","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197703790?lang=zh_cn&edition=full","pubTime":"2026-08-07 10:16","pubTimestamp":1786069006,"startTime":"0","endTime":"0","summary":"8月7日，科伦博泰生物盘中上涨3.15%，报524.0港元，成交额7461.73万港元。消息面上，公司近日公告新型双载荷ADC药物SKB565获国家药监局临床试验批准，用于治疗晚期实体瘤，系公司首个进入临床阶段的双载荷抗体偶联药物，标志着其\"ADC+IO\"一体化策略迈出关键一步。同时，公司将于8月17日召开董事会审议中期业绩，市场对业绩兑现预期升温。此前高盛、摩根大通分别上调目标价至582.95港元及648港元，维持买入评级，多重催化共振推动资金关注度提升。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"科伦博泰生物盘中上涨3.15%，双载荷ADC获批临床叠加中报审议在即","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657505243","title":"港股异动 | 科伦博泰生物(06990)午前涨超4% 新型双载荷ADC药物SKB565新药临床试验申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2657505243","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657505243?lang=zh_cn&edition=full","pubTime":"2026-08-06 11:16","pubTimestamp":1785986197,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科伦博泰生物(06990)午前涨超4%，截至发稿，涨3.8%，报510.5港元，成交额9592.4万港元。消息面上，科伦博泰生物近日发布公告，公司收到国家药品监督管理局药品审评中心的临床试验通知书，同意其新型双载荷ADC药物SKB565的新药临床试验申请，用于治疗晚期实体瘤。这是公司首个进入临床阶段的“双载荷”抗体偶联药物，SKB565的获批标志着公司在“ADC+IO”一体化开发策略上迈出关键一步。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1476639.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["NETL","BK4080","BK4588","KCAI","ADC","BK4585","BMED","LU0196878994.USD","VXUS","IBBQ","PSYK","BK4231","06990","BK1161","MDTX","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168908117","title":"异动解读｜科伦博泰生物盘中上涨3.4%，中报审议在即叠加管线利好密集释放","url":"https://stock-news.laohu8.com/highlight/detail?id=1168908117","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168908117?lang=zh_cn&edition=full","pubTime":"2026-08-06 11:09","pubTimestamp":1785985774,"startTime":"0","endTime":"0","summary":"8月6日，科伦博泰生物盘中上涨3.4%，报509.0港元，成交额8215.75万港元。消息面上，公司8月5日公告将于8月17日召开董事会审议中期业绩，市场对业绩兑现预期升温。此前高盛、摩根大通分别上调目标价至582.95港元及648港元，维持买入评级。多重催化叠加中报窗口临近，推动资金关注度提升。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"科伦博泰生物盘中上涨3.4%，中报审议在即叠加管线利好密集释放","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129051708","title":"科伦博泰生物（06990）拟于2026年8月17日审议中期业绩并举办全球网络电话会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1129051708","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129051708?lang=zh_cn&edition=full","pubTime":"2026-08-05 16:44","pubTimestamp":1785919465,"startTime":"0","endTime":"0","summary":"科伦博泰生物8月5日发布董事会会议通告，公司董事会将于2026年8月17日（星期一）召开会议，议程包括审议并批准本公司及其附属公司截至2026年6月30日止六个月的中期业绩及其发布事宜，并处理其他事项。董事会现任成员包括：董事长兼非执行董事刘革新先生；执行董事葛均友博士；非执行董事刘思川先生、赖德贵先生、冯昊先生、廖益虹女士及曾学波先生；独立非执行董事郑强博士、涂文伟博士、金锦萍博士及李越冬博士。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180051668","title":"科伦博泰生物（06990）再投4亿元认购中行保本结构性存款","url":"https://stock-news.laohu8.com/highlight/detail?id=1180051668","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180051668?lang=zh_cn&edition=full","pubTime":"2026-08-04 20:35","pubTimestamp":1785846937,"startTime":"0","endTime":"0","summary":"2026年8月4日，科伦博泰生物医药股份有限公司公告称，已与中国银行股份有限公司签署《中国银行结构性存款协议III》，以自有闲置资金认购本金4亿元的人民币保本浮动收益结构性存款产品。科伦博泰生物主营肿瘤学、免疫学等领域的创新药物研发、制造及商业化；中国银行股份有限公司为在中国注册的商业银行。双方均确认彼此及其最终实益拥有人与科伦博泰生物及其关联人士之间不存在关联关系。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656556963","title":"科伦博泰生物(06990.HK)认购4亿元中国银行结构性存款","url":"https://stock-news.laohu8.com/highlight/detail?id=2656556963","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656556963?lang=zh_cn&edition=full","pubTime":"2026-08-04 20:33","pubTimestamp":1785846804,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0348805143.USD","LU0196878994.USD","BK1161","LU1328277881.USD","LU1224444064.USD","LU0072462343.USD","BK1521","SG9999004220.SGD","IE00BWDBJ730.SGD","SG9999001093.SGD","LU0307460666.USD","03988","HK0000286598.CNH","LU1497734951.SGD","LU0293314216.USD","LU0651946864.USD","LU1048588211.SGD","LU1813983027.USD","IE00BQJZWZ67.USD","LU1634259557.SGD","LU1051768304.USD","LU1634259391.SGD","LU2097828714.EUR","BK1560","03143","LU0651947912.USD","LU1282651121.HKD","LU1497733631.SGD","06990","LU1051769294.HKD","IE00B19Z5X02.USD","LU2097828557.USD","LU0588546209.SGD","LU2097828631.EUR","LU1282651048.USD","LU2039709279.SGD","LU2097828474.EUR","SG9999006597.SGD","LU1515016050.SGD","LU1497733557.USD","LU2097828805.USD","LU0314109678.HKD","LU1522347837.USD","BK1231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656556950","title":"科伦博泰生物(06990)认购4亿元中国银行结构性存款","url":"https://stock-news.laohu8.com/highlight/detail?id=2656556950","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656556950?lang=zh_cn&edition=full","pubTime":"2026-08-04 20:33","pubTimestamp":1785846804,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物(06990)发布公告，于2026年8月4日，公司订立中国银行结构性存款协议III，据此，公司同意认购本金额为人民币4亿元的中国银行结构性存款III。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475958.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0588546209.SGD","BK0188","BK1231","LU2097828805.USD","LU1048588211.SGD","LU1497733631.SGD","LU1282651048.USD","LU0314109678.HKD","LU0348805143.USD","601988","BK1161","LU1051769294.HKD","BK1521","LU0651947912.USD","BK0012","BK0278","LU1813983027.USD","BK1560","LU1634259391.SGD","BK0015","LU1224444064.USD","LU1497734951.SGD","LU1328277881.USD","LU2097828474.EUR","LU1051768304.USD","HK0000286598.CNH","LU0651946864.USD","LU2097828714.EUR","03988","LU2039709279.SGD","IE00BQJZWZ67.USD","LU0307460666.USD","LU1522347837.USD","LU1515016050.SGD","SG9999004220.SGD","LU0196878994.USD","06990","LU0072462343.USD","IE00B19Z5X02.USD","LU2097828557.USD","SG9999001093.SGD","IE00BWDBJ730.SGD","LU0293314216.USD","LU1497733557.USD","LU1282651121.HKD","SG9999006597.SGD","BK0028","03143","BK0183","LU2097828631.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134837751","title":"科伦博泰生物于2026年8月4日认购中国银行结构性存款III产品，金额达4亿元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=1134837751","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134837751?lang=zh_cn&edition=full","pubTime":"2026-08-04 20:31","pubTimestamp":1785846686,"startTime":"0","endTime":"0","summary":"科伦博泰生物（SKB BIO）宣布，已于2026年8月4日完成对中国银行结构性存款III产品的认购，认购金额为4亿元人民币。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06990","LU0196878994.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195395844","title":"科伦博泰生物7月股份变动月报：新增5,838,000股H股","url":"https://stock-news.laohu8.com/highlight/detail?id=1195395844","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195395844?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:36","pubTimestamp":1785832616,"startTime":"0","endTime":"0","summary":"四川科伦博泰生物医药股份有限公司于2026年8月4日发布了2026年7月股份变动月报。报告显示，截至2026年7月31日，公司注册股本总额为人民币239,023,969元，对应普通股合计239,023,969股，较上月增加5,838,000股H股。根据公告，公司H股股份由上月底的170,984,257股增至176,822,257股，新增的5,838,000股系于2026年7月10日完成配售，内资股数量62,201,712股保持不变。截至7月底，公司H股的公众持股量符合香港联合交易所有限公司相关规则要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180795516","title":"异动解读｜科伦博泰生物盘中上涨3.78%，核心产品TROP2 ADC新增适应症上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1180795516","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180795516?lang=zh_cn&edition=full","pubTime":"2026-07-31 10:04","pubTimestamp":1785463495,"startTime":"0","endTime":"0","summary":"7月31日，科伦博泰生物盘中上涨3.78%，报499.0港元/股，成交额5879.98万港元。消息面上，公司于7月30日公告，核心产品芦康沙妥珠单抗用于PD-L1综合阳性评分＜10或早期接受过PD-1/PD-L1抑制剂的复发或转移性三阴性乳腺癌一线治疗的新增适应症上市申请已获NMPA受理，并纳入优先审评审批程序。此外，合作方默沙东近期启动了芦康沙妥珠单抗联合PD-1/VEGF双抗的II期临床研究，进一步拓展联合用药布局。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"科伦博泰生物盘中上涨3.78%，核心产品TROP2 ADC新增适应症上市申请获受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655827908","title":"科伦博泰生物（06990）旗下芦康沙妥珠单抗新增适应症上市申请获药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2655827908","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655827908?lang=zh_cn&edition=full","pubTime":"2026-07-30 17:23","pubTimestamp":1785403411,"startTime":"0","endTime":"0","summary":"金吾财讯 | 科伦博泰生物 发布公告，公司靶向人滋养细胞表面抗原2的抗体偶联药物芦康沙妥珠单抗（佳泰莱）的一项新增适应症上市申请已获中国国家药品监督管理局药品审评中心受理，用于程序性细胞死亡配体1综合阳性评分＜10或早期阶段接受过程序性细胞死亡蛋白-1╱PD-L1抑制剂的复发或转移性三阴性乳腺癌的一线治疗。这是芦康沙妥珠单抗获NMPA受理的第六项适应症上市申请。","market":"us","thumbnail":"https://static.szfiu.com/news/20250110/YjkxOTY0MzQxMTgyOTU2MzA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/YjkxOTY0MzQxMTgyOTU2MzA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987159","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPOS","BK1161","LU0196878994.USD","06990"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1135996695","title":"科伦博泰生物（06990）TROP2 ADC新适应症上市申请获NMPA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1135996695","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135996695?lang=zh_cn&edition=full","pubTime":"2026-07-30 17:17","pubTimestamp":1785403054,"startTime":"0","endTime":"0","summary":"2026年7月30日，科伦博泰生物宣布，其核心产品TROP2抗体偶联药物蘆康沙妥珠单抗用于“PD-L1综合阳性评分＜10或早期阶段接受过PD-1/PD-L1抑制剂的复发或转移性三阴性乳腺癌一线治疗”的新增适应症上市申请已获国家药品监督管理局药品审评中心受理。该项目已被纳入优先审评审批程序，为蘆康沙妥珠单抗第六项进入该程序的上市申请。蘆康沙妥珠单抗已在中国获批4项适应症，并获得6项突破性疗法认定，是全球首个在肺癌适应症获批上市的TROP2 ADC。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655822168","title":"科伦博泰生物(06990.HK)核心产品TROP2 ADC芦康沙妥珠单抗(sac-TMT)新增适应症上市申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2655822168","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655822168?lang=zh_cn&edition=full","pubTime":"2026-07-30 17:03","pubTimestamp":1785402186,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06990","LU0196878994.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126551070","title":"异动解读｜科伦博泰生物盘中下跌3.01%，报482.6港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1126551070","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126551070?lang=zh_cn&edition=full","pubTime":"2026-07-30 10:38","pubTimestamp":1785379085,"startTime":"0","endTime":"0","summary":"7月30日，科伦博泰生物盘中下跌3.01%，报482.6港元/股，成交额5705.1万港元。科伦博泰生物所在的生物科技行业中，板块整体走弱，个股中，信达生物跌1.9%，康方生物跌2.25%，百济神州跌1.71%，三生制药跌2.06%，荣昌生物跌3.2%。科伦博泰生物是一家主要从事肿瘤学、免疫学及其他治疗领域创新药物研发、制造及商业化的公司，核心产品包括抗体药物偶联物（ADC）SKB264等，主要用于乳腺癌、非小细胞肺癌、胃肠道癌等疾病的治疗。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655189942","title":"默沙东卡位ADC+IO2.0! 科伦博泰TROP2 ADC联合PD-1/VEGF双抗的II期临床启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2655189942","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655189942?lang=zh_cn&edition=full","pubTime":"2026-07-29 18:11","pubTimestamp":1785319860,"startTime":"0","endTime":"0","summary":"来源：医药魔方Info近期，默沙东官网新增TROP2 ADC芦康沙妥珠单抗联合PD-1/VEGF双抗MK-2010治疗晚期实体瘤患者的一项开放标签II期临床研究MK-2010-003。而此次默沙东新开的MK-2010-003研究以芦康沙妥珠单抗和PD-1/VEGF双抗MK-2010为试验药物，探索该联用组合在实体瘤患者的疗效与安全性。默沙东此次快速卡位“ADC+IO2.0”双抗联合赛道，不仅是其全球研发战略的关键落子，也标志着中国本土创新ADC药物正加速融入国际主流治疗体系。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hyyj/2026-07-29/doc-iniknvxc5662188.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2106854487.HKD","SG9999014575.USD","LU0070302665.USD","SG9999014567.USD","LU0985320562.USD","SG9999015341.SGD","LU1941712264.USD","LU0196878994.USD","LU1983299246.USD","LU2125154935.USD","LU0211331839.USD","VHT","LU2361044949.HKD","LU1430594728.SGD","LU1291159041.SGD","XLV","LU1057294990.SGD","LU0058720904.USD","PPH","BK4588","LU2360032135.SGD","LU0942090050.USD","IE0009355771.USD","BK1161","GDOC","LU2491049909.HKD","LU0432979614.USD","SG9999001440.SGD","LU1037948897.HKD","LU0266013472.USD","BK4559","LU0859254822.USD","JDOC","LU1974910355.USD","BK4550","LU2125909247.SGD","LU2433249047.HKD","LU1989772923.USD","FTXH","IE0002141913.USD","IE00BLSP4239.USD","LU1929549753.HKD","MRK","LU0965508806.USD","LU0980610538.SGD","LU2023250843.SGD","SG9999014559.SGD","LU0265550359.USD","SG9999013999.USD","IE00BBT3K403.USD","IE00BN8TJ469.HKD","06990","LU0006306889.USD","LU2023250504.SGD","LU0098860793.USD","LU0648001328.SGD","LU1066051811.HKD","LU1585245621.USD","IE00BFTCPJ56.SGD","LU0965509101.SGD","LU1093756168.USD","SG9999002224.SGD","LU1066051225.USD","IE00B1BXHZ80.USD","FHLC","IE00BSNM7G36.USD","LU1162221912.USD","LU1934455863.HKD","LU0689626769.HKD","LU2324357040.USD","LU0868494708.USD","LU0965509283.SGD","IYH","LU1023059063.AUD","LU1066051498.USD","LU0130517989.USD","LU2125909593.SGD","LU0861579265.USD","LU1116320901.HKD","LU1934455277.USD","LU0106261372.USD","LU0320765646.SGD","BK4007","LU1201861249.SGD","LU2361044865.SGD","LU0238689110.USD","LU2468319806.SGD","LU2112291526.USD","LU1917777945.USD","RXL","LU0208291251.USD","SG9999002232.USD","LU1923622614.USD","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","LU0130102774.USD","LU1035773651.USD","LU1934455194.USD","LU1069347547.HKD","LU1989771016.USD","IE00BLSP4452.SGD","LU2461242641.AUD","LU2125154778.USD","LU2491050154.USD","IE000M9KFDE8.USD","BK4516","BK4585","LU1989772840.SGD","TRUH","LU0289739699.SGD","SG9999014542.SGD","LU0965509010.AUD","LU1037948541.HKD","LU1699723380.USD","SG9999001176.SGD","BK4534","LU2089984988.USD","LU0234572021.USD","LU2357627491.SGD","SG9999001176.USD","LU0124676726.USD","BMED","HRTS","LU0265550946.USD","LU1061106388.HKD","SG9999015358.SGD","LU0320765489.SGD","IE00BJT1NW94.SGD","LU1571399168.USD","LU0203345920.USD","LU1941712348.USD","PAWZ","SGXZ57979304.SGD","LU0203347892.USD","LU1116320737.USD","LU2361045086.USD","LU2491050071.SGD","IHE","LU0122379950.USD","BK4533","LU0868494617.USD","LU1066053197.SGD","LU0477156953.USD","LU1093756325.SGD","IXJ","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654458022","title":"【券商聚焦】交银国际：下半年医药板块有望迎来修复 但内部分化或持续加大","url":"https://stock-news.laohu8.com/highlight/detail?id=2654458022","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654458022?lang=zh_cn&edition=full","pubTime":"2026-07-28 10:01","pubTimestamp":1785204072,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，近一个月恒生医疗保健指数涨17.4%，跑赢大市。其中，生物药、CXO及处方药板块表现较优于其他板块。机构持仓方面，2026年年中以来，内资持仓延续提升态势，而外资则略有降低。该机构指，中报季临近，7月以来多家公司业绩预告陆续发布，CXO板块表现亮眼，业绩和订单延续高增长态势。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986903","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013","09939","02268","LU0588546209.SGD","LU2039709279.SGD","03692","03329","BK1587","09996","06990","01530","02096","LU0348783233.USD","LU0196878994.USD","LU0417516571.SGD","02273","LU0572944931.SGD","01548","KURE","01276","LU1720050803.USD","BK1521","03759","LU2476274308.USD","LU0634319403.HKD","LU2097828714.EUR","02269","06160","HK0000320223.HKD","LU1880383366.USD","LU2328871848.SGD","09926","01177","01952","LU1813983027.USD","02596","LU0856984785.SGD","01951","HK0000165453.HKD","LU2399975544.HKD","01801","KCE","06821","06996","09966","02162","01093","06078","BK1219","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159541447","title":"科伦博泰获NMPA临床试验批准，SKB565用于治疗晚期实体瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1159541447","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159541447?lang=zh_cn&edition=full","pubTime":"2026-07-27 21:36","pubTimestamp":1785159417,"startTime":"0","endTime":"0","summary":"科伦博泰生物（6990.HK）近日迎来重大利好。该公司自主研发的候选药物SKB565，已正式获得中国国家药品监督管理局（NMPA）的临床试验默示许可（IND）。此次获批的适应症，是针对晚期实体瘤的治疗。\n这笔临床试验的批准，无疑为科伦博泰的研发管线注入了新的活力。SKB565作为一款在研药物，其未来的临床进展值得市场关注。目前，围绕该药物的更多细节，仍有待公司后续进一步披露。\n此次IND获批，是科伦博泰在肿瘤治疗领域布局的又一重要里程碑。随着临床试验的推进，SKB565能否在众多同类药物中脱颖而出，展现出优异的疗效与安全性，将直接决定其未来的市场潜力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1979443071.USD","LU0196878994.USD","BK0239","002422","LU1064131003.USD","LU2148510915.USD","BK0060","BK1161","LU1934453819.USD","06990","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128365225","title":"科伦博泰生物获NMPA批准SKB565用于治疗晚期实体瘤的IND申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1128365225","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128365225?lang=zh_cn&edition=full","pubTime":"2026-07-27 18:48","pubTimestamp":1785149302,"startTime":"0","endTime":"0","summary":"四川科伦博泰生物医药股份有限公司（06990.HK）近日宣布，其自主研发的候选药物SKB565已获得中国国家药品监督管理局（NMPA）的临床试验申请（IND）批准。该药物旨在用于治疗晚期实体瘤。这一里程碑标志着公司在肿瘤治疗领域的研发管线迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06990","LU0196878994.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654501114","title":"科伦博泰生物(06990)：SKB565新药临床试验申请获国家药品监督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2654501114","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654501114?lang=zh_cn&edition=full","pubTime":"2026-07-27 18:45","pubTimestamp":1785149110,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物 发布公告，本公司已收到国家药品监督管理局药品审评中心同意新型双载荷ADC药物SKB565新药临床试验申请的临床试验通知书，用于治疗晚期实体瘤。凭藉在ADC领域的技术沉淀与平台优势，本公司已布局一系列结合高价值靶点、差异化设计并具备全球潜力的创新分子。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472679.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BMED","PSYK","06990","IBBJ","BK1161","LU0196878994.USD","IBBQ","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136850383","title":"异动解读｜科伦博泰生物盘中上涨3.03%，投行密集上调目标价叠加公募举牌潮延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1136850383","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136850383?lang=zh_cn&edition=full","pubTime":"2026-07-22 09:56","pubTimestamp":1784685409,"startTime":"0","endTime":"0","summary":"7月22日，科伦博泰生物盘中上涨3.03%，报527.0港元，成交额1.44亿港元。消息面上，近期多家国际投行密集上调公司目标价，摩根大通将目标价由535港元上调至648港元，高盛上调至582.95港元并维持\"买入\"评级，均看好核心产品sac-TMT的全球商业化前景。与此同时，汇添富等多家头部公募机构密集增持港股创新药标的，科伦博泰生物获增持后公募持股比例已触及5%举牌线，机构长线资金持续流入强化市场信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读｜科伦博泰生物盘中上涨3.03%，投行密集上调目标价叠加公募举牌潮延续","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://kelun-biotech.com","stockEarnings":[{"period":"1week","weight":0.0344},{"period":"1month","weight":0.0548},{"period":"3month","weight":0.2036},{"period":"6month","weight":0.2554},{"period":"1year","weight":0.256},{"period":"ytd","weight":0.3399}],"compareEarnings":[{"period":"1week","weight":-0.0052},{"period":"1month","weight":0.0434},{"period":"3month","weight":-0.0218},{"period":"6month","weight":-0.0441},{"period":"1year","weight":-0.0085},{"period":"ytd","weight":-0.0091}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"四川科伦博泰生物医药股份有限公司是一家主要从事新药业务的研发、生产和销售的中国公司。该公司主要从事肿瘤学、免疫学及其他治疗领域的创新药物的研发、制造及商业化。该公司的产品有抗体药物偶联物（ADC）SKB264和A166等。该公司产品主要用于乳腺癌、非小细胞肺癌、胃肠道癌等疾病的治疗。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.05939},{"month":2,"riseRate":0.666667,"avgChangeRate":0.239909},{"month":3,"riseRate":1,"avgChangeRate":0.292496},{"month":4,"riseRate":1,"avgChangeRate":0.083557},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.011152},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.022649},{"month":7,"riseRate":0.666667,"avgChangeRate":0.111158},{"month":8,"riseRate":1,"avgChangeRate":0.057142},{"month":9,"riseRate":1,"avgChangeRate":0.084769},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.03489},{"month":11,"riseRate":1,"avgChangeRate":0.072292},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.053467}],"exchange":"SEHK","name":"科伦博泰生物","nameEN":"SKB BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科伦博泰生物(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科伦博泰生物(06990)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科伦博泰生物,06990,科伦博泰生物股票,科伦博泰生物股票老虎,科伦博泰生物股票老虎国际,科伦博泰生物行情,科伦博泰生物股票行情,科伦博泰生物股价,科伦博泰生物股市,科伦博泰生物股票价格,科伦博泰生物股票交易,科伦博泰生物股票购买,科伦博泰生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科伦博泰生物(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科伦博泰生物(06990)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}